BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

PURPOSE: Acute B-lymphoblastic leukemia (B-ALL) is a malignant disease characterized by accumulation of clonal immature lymphocytes in the bone marrow and peripheral blood. The approval of BCR::ABL1 tyrosine kinase inhibitors (TKI) such as imatinib, dasatinib, nilotinib and ponatinib marked a milest...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauer, Joseph, Märklin, Melanie, Pflügler, Martin, Hörner, Sebastian, Hinterleitner, Clemens, Tandler, Claudia, Jung, Gundram, Salih, Helmut R., Heitmann, Jonas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470724/
https://www.ncbi.nlm.nih.gov/pubmed/35551463
http://dx.doi.org/10.1007/s00432-022-04039-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470724/
https://www.ncbi.nlm.nih.gov/pubmed/35551463
http://dx.doi.org/10.1007/s00432-022-04039-5

Ejemplares similares